A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Glycopyrrolate (Primary) ; Indacaterol
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Registrational
- Acronyms GEM3
- Sponsors Novartis
- 01 Jun 2016 Results published in the Respiratory Medicine
- 20 Jan 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.
- 07 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 Nov 2014, according to ClinicalTrials.gov